Pharmasia last traded at ₹83.00 (2026-10-13). Over the past month the stock moved -5.7%, three months the stock moved +1.8%, year the stock moved +101.5%. Its closing range over 52 weeks is ₹33.47 – ₹129.20, with the latest close 35.8% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1981, Phaarmasia Ltd is engaged in manufacturing and marketing of Cosmetics, Oral Contraceptive Pills (OCP) and Combipack with Iron Tablets
OCP-Led Pharmaceutical Business:[1] Phaarmasia primarily manufactures and sells oral contraceptive pills, with other products including cosmetics and combi packs with iron tablets. In FY25, government and other OCP sales contributed ₹18.57 Cr, or about 76% of the company's ₹24.37 crore operating revenue.[2] -Unit I Divestment Changed the Manufacturing Base:[3] Shareholders approved the sale of Unit I's land and building for at least ₹25 crore to fund business requirements, including working capital, debt reduction and facility upgrades.[4] The unit was transferred during December 2025 quarter; FY26 recorded ₹25.83 crore of sale proceeds and a ₹18.99 crore exceptional gain, while property, plant and equipment fell from ₹12.28 crore to ₹1.03 crore.[5][6][7]
In the latest quarter (Jun 2026), Pharmasia reported sales of ₹8.28 crore (+20.5%) and net profit of ₹0.34 crore (+25.9%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 8.28 | 0.05 | 0.60 | 0.34 | 0.50 |
| Mar 2026 | 7.73 | -0.66 | -8.54 | -0.70 | -1.03 |
| Dec 2025 | 16.05 | 0.84 | 5.23 | 16.27 | 23.83 |
| Sep 2025 | 16.55 | 1.61 | 9.73 | 1.74 | 2.55 |
| Jun 2025 | 6.87 | 0.09 | 1.31 | 0.27 | 0.40 |
| Mar 2025 | 5.43 | -0.61 | -11.23 | -0.53 | -0.78 |
| Dec 2024 | 4.72 | -0.79 | -16.74 | -0.70 | -1.03 |
| Sep 2024 | 5.93 | -0.79 | -13.32 | -0.64 | -0.94 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -31.4% | -7.1% | -45.6% | -17.1% | +179.1% | +240.0% | +42.4% | +20.5% |
| Operating profit growth | – | – | -284.8% | -50.0% | – | – | – | -44.4% |
| Net profit growth | – | – | -212.8% | -3.6% | – | – | – | +25.9% |
| EPS growth | – | – | -213.0% | -2.4% | – | – | – | +25.0% |
| OPM % | -13.3% | -16.7% | -11.2% | 1.3% | 9.7% | 5.2% | -8.5% | 0.6% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Pharmasia reported sales of ₹47.00 crore (+92.9%) and net profit of ₹18.00 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 47.00 | 2.00 | 4.00 | 18.00 | 25.74 |
| Mar 2025 | 24.37 | -2.01 | -8.25 | -1.59 | -2.33 |
| Mar 2024 | 30.59 | -0.82 | -2.68 | -0.52 | -0.76 |
| Mar 2023 | 27.42 | -1.55 | -5.65 | -1.26 | -1.85 |
| Mar 2022 | 16.88 | -1.74 | -10.31 | -1.55 | -2.27 |
| Mar 2021 | 16.20 | -0.06 | -0.37 | 0.31 | 0.45 |
| Mar 2020 | 19.93 | 0.82 | 4.11 | 0.54 | 0.79 |
| Mar 2019 | 23.97 | 0.73 | 3.05 | 0.78 | 1.14 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +26.4% | -16.9% | -18.7% | +4.2% | +62.4% | +11.6% | -20.3% | +92.9% |
| Operating profit growth | +10.6% | +12.3% | -107.3% | – | – | – | – | – |
| Net profit growth | +36.8% | -30.8% | -42.6% | -600.0% | – | – | – | – |
| EPS growth | +37.3% | -30.7% | -43.0% | -604.4% | – | – | – | – |
| OPM % | 3.1% | 4.1% | -0.4% | -10.3% | -5.7% | -2.7% | -8.3% | 4.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Pharmasia.
Get Free AI Stock Analysis FREE →No recent news available for Pharmasia.
Pharmasia shares were last quoted at ₹83.00 (-9.8% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Pharmasia has a price-to-earnings (P/E) ratio of 3.48 and a price-to-book (P/B) ratio of 2.74. The industry P/E is 53.45.
The 52-week high of Pharmasia is ₹131.75 and the 52-week low is ₹30.01.
The market capitalisation of Pharmasia is about ₹61.44 crore.
In the latest quarter (Jun 2026), Pharmasia reported sales of ₹8.28 crore (+20.5%) and net profit of ₹0.34 crore (+25.9%), compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Pharmasia has a 3-year ROE of 0.00%, 3-year profit growth of 53.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 73.51% of Pharmasia.
Pharmasia belongs to the Pharmaceuticals & Drugs sector.